Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.74 |
| ▸ | WDR5 | P61964 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | CPT2 | P23786 | 1/20 | 0.47 |
| ▸ | CPT1A | P50416 | 1/20 | 0.47 |
| ▸ | CPT1B | Q92523 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2334954 | 0.86 | WDR5 (0.68) | ALDH1A1WDR5MAPTNPSR1KMT2A | |
| SCHEMBL2170413 | 0.81 | FFAR4 (0.63) | ALDH1A1MAPTNPSR1KMT2AMEN1 | |
| SCHEMBL7157627 | 0.80 | ALDH1A1 (0.53) | ALDH1A1WDR5MAPTNPSR1KMT2A | |
| SCHEMBL5059972 | 0.79 | KMT2A (0.57) | ALDH1A1WDR5MAPTNPSR1KMT2A | |
| SCHEMBL28678247 | 0.76 | HDAC2 (0.60) | ALDH1A1WDR5MAPTKMT2AMEN1 | |
| SCHEMBL3320242 | 0.72 | MAPT (0.73) | ALDH1A1MAPTNPSR1KMT2AMEN1 | |
| SCHEMBL11096707 | 0.71 | KMT2A (0.56) | ALDH1A1MAPTNPSR1KMT2AMEN1 | |
| SCHEMBL21916046 | 0.71 | MAPT (0.50) | ALDH1A1MAPTNPSR1KMT2AMEN1 | |
| SCHEMBL9119300 | 0.71 | ALDH1A1 (0.54) | ALDH1A1MAPTNPSR1KMT2AMEN1 | |
| SCHEMBL12903989 | 0.70 | MAPT (0.66) | ALDH1A1MAPTNPSR1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050080139-A1 | Naaladase inhibitors for treating huntington's disease | GUILFORD PHARMACEUTICALS INC. | 2005-04-14 | — | — | US | claimed |
| US-20040186081-A1 | Naaladase inhibitors for treating opioid tolerance | GUILFORD PHARMACEUTICALS INC. | 2004-09-23 | — | — | US | claimed |
| WO-2004078180-A2 | NAALADASE INHIBITORS FOR TREATING OPIOID TOLERANCE | GUILFORD PHARMACEUTICALS INC. (US) | 2004-09-16 | — | — | WO | claimed |
| WO-2003057154-A2 | NAALADASE INHIBITORS FOR TREATING HUNTINGTON'S DISEASE | GUILDFORD PHARMACEUTICALS INC. (US) | 2003-07-17 | — | — | WO | claimed |
| US-20030083505-A1 | Spinal cord injury, demyelinating diseases, Parkinson's disease, Amyotrophic Lateral Sclerosis, alcohol, nicotine, cocaine dependence, neuropathy, pain and schizophrenia; antiischemic, - carcinogenic agents; NAALADase inhibitors | EISAI INC. | 2003-05-01 | — | — | US | claimed |
| EP-1292601-A2 | NAALADASE INHIBITORS FOR TREATING RETINAL DISORDERS AND GLAUCOMA | GUILFORD PHARMACEUTICALS INC. (US) | 2003-03-19 | — | — | EP | claimed |
| US-20030036534-A1 | Naaladase inhibitors for treating retinal disorders and glaucoma | EISAI INC. | 2003-02-20 | — | — | US | claimed |
| US-6452044-B2 | NERVOUS SYSTEM AND PSYCHOLOGICAL DISORDERS | GUILFORD PHARMACEUTICALS INC. | 2002-09-17 | — | — | US | claimed |
| US-20020019430-A1 | Nervous system and psychological disorders | EISAI INC. | 2002-02-14 | — | — | US | claimed |
| US-20020013295-A1 | Naaladase inhibitors for treating amyotrophic lateral sclerosis | GUILFORD PHARMACEUTICALS INC., A DELAWARE CORPORATION | 2002-01-31 | — | — | US | claimed |
| WO-2001092274-A2 | NAALADASE INHIBITORS FOR TREATING RETINAL DISORDERS AND GLAUCOMA | GUILFORD PHARMACEUTICALS INC. (US) | 2001-12-06 | — | — | WO | claimed |
| EP-4448629-A1 | FUNCTIONALIZED GRAPHENE STRUCTURE AND NANOCOMPOSITE COMPRISING SUCH FUNCTIONALIZED GRAPHENE STRUCTURE | Glenntex AB (SE) | 2024-10-23 | — | — | EP | disclosed |
| WO-2023113679-A1 | FUNCTIONALIZED GRAPHENE STRUCTURE AND NANOCOMPOSITE COMPRISING SUCH FUNCTIONALIZED GRAPHENE STRUCTURE | GLENNTEX AB (SE) | 2023-06-22 | — | — | WO | disclosed |
| US-7220780-B2 | Naaladase inhibitors for treating retinal disorders and glaucoma | GUILFORD PHARMACEUTICALS INC. (US) | 2007-05-22 | — | — | US | disclosed |
| US-20050171065-A1 | NAALADas, N-Acetylated-Alpha-Linked-Acidic-Dipeptidase inhibitors; 5-phosphonomethyl-1,3-benzenedicarboxylic Acid; glutamate abnormalities, anticancer, antidiabetic agent, angiogenesis inhibitor, neuropathy, pain, compulsive disorders, prostate diseases, glaucoma | GUILFORD PHARMACEUTICALS INC. | 2005-08-04 | — | — | US | disclosed |
| US-20020013295-A1 | Naaladase inhibitors for treating amyotrophic lateral sclerosis | GUILFORD PHARMACEUTICALS INC., A DELAWARE CORPORATION | 2002-01-31 | — | — | US | disclosed |
| WO-2001092274-A2 | NAALADASE INHIBITORS FOR TREATING RETINAL DISORDERS AND GLAUCOMA | GUILFORD PHARMACEUTICALS INC. (US) | 2001-12-06 | — | — | WO | disclosed |
| WO-2001091738-A2 | NAALADASE INHIBITORS FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS | GUILFORD PHARMACEUTICALS INC. (US) | 2001-12-06 | — | — | WO | disclosed |
| EP-1091958-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2001-04-18 | — | — | EP | disclosed |
| WO-2000001692-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2000-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013295-A1 | Naaladase inhibitors for treating amyotrophic lateral sclerosis | SMN1; SMN2, GAA, NAALAD2 | ALDH1A1 814/4885WDR5 1695/4885MAPT 11/4885 |
| US-20030083505-A1 | Spinal cord injury, demyelinating diseases, Parkinson's disease, Amyotrophic Lateral Sclerosis, alcohol, nicotine, cocaine dependence, neuropathy, pain and schizophrenia; antiischemic, - carcinogenic agents; NAALADase inhibitors | NGF, GAP43, ACHE | ALDH1A1 110/4885WDR5 2464/4885MAPT 129/4885 |
| US-20050080139-A1 | Naaladase inhibitors for treating huntington's disease | HTT, GAA, ADA | ALDH1A1 944/4885WDR5 989/4885MAPT 16/4885 |
| US-20050171065-A1 | NAALADas, N-Acetylated-Alpha-Linked-Acidic-Dipeptidase inhibitors; 5-phosphonomethyl-1,3-benzenedicarboxylic Acid; glutamate abnormalities, anticancer, antidiabetic agent, angiogenesis inhibitor, neuropathy, pain, compulsive disorders, prostate diseases, glaucoma | NAALAD2, GLUL, DNPEP | ALDH1A1 117/4885WDR5 1365/4885MAPT 433/4885 |
| US-20020019430-A1 | Nervous system and psychological disorders | GLUL, DDC, DNPEP | ALDH1A1 228/4885WDR5 2365/4885MAPT 346/4885 |
| US-20040186081-A1 | Naaladase inhibitors for treating opioid tolerance | OPRD1, OPRK1, OPRM1 | ALDH1A1 105/4885WDR5 1818/4885MAPT 434/4885 |
| US-20030036534-A1 | Naaladase inhibitors for treating retinal disorders and glaucoma | ALDH1A2, GAA, PDE6A | ALDH1A1 198/4885WDR5 1599/4885MAPT 266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.